BergenBio Fundamentale Forhold (BGBIO)

TekBot · november 9, 2021, 3:31pm

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 9 November 2021

The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) have, to
…

Vis børsmeldingen

fulfil the Company’s obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, resolved to increase the Company’s share capital by NOK 7,000 by issuance
of 70,000 new shares. The new shares are subscribed for by option owners who
wishes and are entitled to exercise options in accordance with the Company’s
option scheme. Each option gives a right to receive one share in the Company.
The subscription price is in accordance with the prevailing options price
pursuant to the Company´s option scheme, in average NOK 15.00 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,845,525.50 consisting of 88,455,255 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

vcp · november 13, 2021, 10:45pm

Du jobber utrettelig💪 Håper Merck kjenner på sulten! En fase 3 partneravtale hadde smakt av fugl.

Fast track i både NSCLC og AML!
Må kunne sies å være en fantastisk validering av bemcentinib.

Så har vi alle de andre studiene i tillegg.

Verdsettelsen av selskapet derimot, synest å reflektere noe helt annet.

Ser fram til q3 presentasjon mandag!

larosaleda · november 16, 2021, 6:23am

https://newsweb.oslobors.no/message/546936

AML confirmayory trial H2 2022
NSCLC 1b i H1 2022. 1L ( STK11)
COVID multinational collaboration H1.

TekBot · november 17, 2021, 4:51pm

BerGenBio ASA: Share capital increase

Bergen, Norway, 17 November 2021 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 9 November
2021 where the Company announced that the board of directors of the Company had
…

Vis børsmeldingen

resolved to increase the Company’s share capital in connection with the exercise
of options pursuant to the Company’s share option program. A total of 70,000
options were exercised and 70,000 new shares were issued at an average
subscription price of NOK 15.00 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company’s share capital
is NOK 8,845,525.50 divided into 88,455,255 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

Kilde

tverilytt · november 27, 2021, 5:06pm

https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20211116_4

Tekspert · desember 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@anon28800809 (680 likes)

@Roc (308 likes)

@Hayen (120 likes)

Resten av topp 10:

@vcp (107 likes)
@Multiple (67 likes)
@Scrivener (64 likes)
@Ekornet (63 likes)
@larosaleda (51 likes)
@Fornybar (47 likes)
@Matadoren (44 likes)

Gratulerer!

TekBot · desember 13, 2021, 2:00pm

BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING

Bergen, Norway, 13 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE:
BGBIO), a clinical-stage biopharmaceutical company developing novel, selective
AXL kinase inhibitors for severe unmet medical needs, is pleased to announce
…

Vis børsmeldingen

that it is presenting updated data from the Company’s Phase II study of
bemcentinib (BCBC003) in a poster presentation today at the 63rd Annual American
Society of Hematology (ASH) Meeting.

Professor Sonja Loges will provide an update from the Company’s Phase II study
(BGBC003) of bemcentinib in combination with low dose cytarabine (LDAC) in
older, relapsed and refractory AML patients unfit for intensive chemotherapy.

The data presented indicate that bemcentinib in combination with LDAC is well
tolerated and offers meaningful clinical benefits. Translational research has
identified immune-based activity associated with response to treatment,
demonstrating that bemcentinib elicits activation of CD8+ T cells and B
cells/plasma cells, two major adaptive immune cell populations responsible for
anti-AML immune responses. Survival data measured as median Overall Survival
(mOS) in older unfit relapsed AML patients looks encouraging compared to
historical controls all through not yet matured.

Professor Sonja Loges, Chief Investigator of the BGBC003 trial commented: “The
data on relapsed AML patients who currently have very few treatment options, is
very encouraging. These results affirm our belief that the combination of
bemcentinib and LDAC provides meaningful clinical benefits.”

Details of the presentation:

Title: Bemcentinib (Oral AXL Inhibitor) in combination with Low-dose Cytarabine
Is Well Tolerated and Efficacious in Older Relapsed AML Patients. Updates from
the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results
indicating Bemcentinib elicits anti-AML immune responses.

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding
Transplantation and Cellular Immunotherapies: Poster III

Time, Location: 6.00 - 8.00 PM Eastern, Georgia World Congress Center, Hall B5

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Boms · desember 13, 2021, 2:45pm

Virker jo lovende dette:

Gj.sn. alder på pasientene er 76 år, så man kan neppe forvente større økning i respons/overlevelse enn dette.

Realize_1 · desember 13, 2021, 2:56pm

Ser på posteren at «survival data continues to mature».

TekBot · desember 14, 2021, 6:44am

BerGenBio to present at DNB Nordic Healthcare Conference 2021

Bergen, Norway, 14 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE:
BGBIO), a clinical-stage biopharmaceutical company developing novel, selective
AXL kinase inhibitors for severe unmet medical needs, is pleased to announce
…

Vis børsmeldingen

that it will be presenting at the 12th DNB Nordic Healthcare Conference on 16th
December 2021.

The presentation will take place from 11:35 CET and will be made available on
the Company website: www.bergenbio.com/investors/presentations/

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

alfred_e_neuman · desember 14, 2021, 10:53pm

AXL receptor is required for Zika virus strain MR-766 infection in human glioblastoma cell lines

Published: November 10, 2021

https://www.cell.com/molecular-therapy-family/oncolytics/fulltext/S2372-7705(21)00150-9 (DOI)

Recent reports have shown that Zika virus (ZIKV) has oncolytic potential against human glioblastoma (GBM); however, the mechanisms underlying its tropism and cell entry are not completely understood. The receptor tyrosine kinase AXL has been identified as an entry receptor for ZIKV in a cell-type-specific manner. Interestingly, AXL is frequently overexpressed in GBM patients. Using commercially available GBM cell lines, we first show that cells expressing AXL are permissive for ZIKV infection, while cells that do not express AXL are not.

Furthermore, inhibition of AXL kinase using R428 and antibody blockade of AXL receptor strongly attenuated virus entry in GBM cell lines. Additionally, CRISPR knockout of the AXL gene in GBM cell lines completely abolished ZIKV infection, significantly inhibited viral replication, and significantly reduced apoptosis compared with parental lines. Lastly, introduction of AXL receptor into non-expressing cell lines renders the cells susceptible to ZIKV infection.

Together, these findings demonstrate that ZIKV entry into GBM cells in vitro is mediated by the AXL receptor and that following cell entry, productive infection is cytotoxic. Thus, ZIKV is a potential oncolytic virus for GBM.

(Bemcentinib, also known as BGB324 or R428)

Ekornet · desember 15, 2021, 6:07pm

Blir spennende å få resultatene fra Glioblastom studien i USA, tipper mot slutten av 2022.

TekBot · desember 16, 2021, 6:31am

BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center

In-Licensing further strengthens intellectual property estate for the treatment
of Non-Small Cell Cancer (NSCLC) patients with STK11 mutations

…

Vis børsmeldingen

Bergen, Norway, 16 December 2021- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announced today the licensing of certain intellectual
property from the UT Southwestern Medical Center. The exclusive license to
intellectual property generated by researchers at UT Southwestern Medical Center
supports the Company’s existing IP position underlying use of AXL inhibitors,
including its lead product candidate bemcentinib, for the treatment of patients
harboring STK11 mutations in NSCLC. No financial terms have been disclosed.

The STK11 mutation is observed in up to 20% of NSCLC patients. STK11 is an
important tumor suppressor gene associated with a poor prognosis in NSCLC
patients and which has been reported in some studies to confer resistance to
immune checkpoint inhibitors.

Researchers at the UT Southwestern Medical Center and BerGenBio recently
presented data at the 2021 Society for Immunotherapy of Cancer (SITC) 36thAnnual
Meeting exploring why patients harboring a mutation to the STK11 gene may not
respond to anti-PD1 therapy, a commonly used treatment in first line NSCLC
patients. Preclinical research further indicated that the addition of the
selective AXL inhibitor bemcentinib restored the activity of anti-PD1 treatment
in relevant lung cancer models

Martin Olin, Chief Executive Officer at BerGenBio, commented: “The license
agreement with UT Southwestern Medical Center complements our existing
intellectual property filings in this important patient population which appears
to poorly respond to anti-PD1 therapy. We will continue to explore how this
target group might be addressed by the combination of bemcentinib and an immune
checkpoint inhibitor.”

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · desember 16, 2021, 2:01pm

BerGenBio ASA: Notice of Extraordinary General Meeting

Bergen, Norway, 16 December 2021 - Notice is hereby given that an Extraordinary
General Meeting in BerGenBio ASA (OSE:BGBIO) will be held on 6 January 2022 at
10:00 hours (CET).
…

Vis børsmeldingen

The notice, registration form and power of attorney are attached to this

release. The notice will be sent to all registered shareholders and is
available at https://www.bergenbio.com/investors/general-
meetings/ (General Meetings - BerGenBio)

All shareholders are encouraged to exercise their shareholder rights. Due to the
ongoing corona virus pandemic, the Board encourages shareholders not to attend
the general meeting in person, but rather to make use of the ability to vote by
proxy.The proxy form is attached to this release and available on the Company’s
website: General Meetings - BerGenBio

The following items are on the agenda: (i) Election of new Chair of the Board of
Directors and changes to the board (ii) Remuneration to the chair of the board.

We encourage all shareholders to register as electronical user in VPS to save
environment impact.

-Ends-

Contacts

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing
companion diagnostic tests to potentially identify patient populations most
likely to benefit from AXL inhibition. This is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · desember 17, 2021, 12:44pm

Financial calendar

Tekspert · januar 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@anon28800809 (741 likes)

@Roc (303 likes)

@Hayen (127 likes)

Resten av topp 10:

@Scrivener (85 likes)
@vcp (85 likes)
@Direkte (73 likes)
@Multiple (67 likes)
@Realize_1 (66 likes)
@PankPinter (58 likes)
@Ekornet (53 likes)

Gratulerer!

TekBot · januar 6, 2022, 7:58am

BerGenBio - Mandatory notification of trade by Primary Insiders

vcp · januar 6, 2022, 9:07am

Må mangle en desimal der, skal markedet få troen på at CEO, har overbevisningen.

Walk the talk.

Men riktignok bedre enn Godfrey.

Zuba · januar 6, 2022, 9:10am

Sign on fee det der. så det er du og jeg som har kjøpt til han sånn i grove trekk:joy:

vcp · januar 6, 2022, 9:12am

Ikke verd vatten då